Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
Clinical trial NCT02686762 · COMPLETED
Trial details
- NCT number
- NCT02686762
- Sponsor
- Conatus Pharmaceuticals Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-26
- Primary completion
- 2019-01-29
- Enrollment
- 318
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.